Viral pathogenesis of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common tumors in the world with an estimated 500 000–1000 000 new cases per year.1 Although less frequent in the USA and Europe, these tumors have an annual incidence of up to 500 cases per 100 000 population in certain regions of Asia and sub-Saharan Africa. The reasons for this high incidence are chronic infections with the hepatitis B virus (HBV) or the hepatitis C virus (HCV) as well as HBV–HCV co-infections.2–9 The clinical course of HBV and HCV infection depends in part on molecular characteristics of the viruses,10 in part on the patients’ HLA haplotype,11–14 and in part on other coexisting risk factors. Well-recognized non-viral exogenous agents associated with the pathogenesis of HCC are alcohol and aflatoxins. In the West, alcohol-induced liver injury is a leading cause of liver cirrhosis and the most important HCC risk factor.15 In southern China and Africa, dietary ingestion of high levels of aflatoxin B1 may represent a special environmental hazard, particularly in chronic HBV carriers.16–19 Other exogenous factors have also been incriminated and include dietary iron overload,20 long-term use of oral contraceptives21,22 and high-dose anabolic steroids. The development of hepatic cirrhosis, particularly in association with genetic diseases, such as α-1-antitrypsin deficiency or hemochromatosis, place the individual at a greatly increased risk for the malignant transformation of hepatocytes. In the following, the role of HBV and HCV in the pathogenesis of HCC and strategies aimed at the prevention of HCC will be discussed. The major clinical risk factor for HCC development is liver cirrhosis because 70–90% of HCC develop in a macronodular cirrhosis. The HCC risk in patients with liver cirrhosis depends on the activity, duration and the etiology of the underlying liver disease (Fig. 1). In addition, HCC are more frequent in men than in women and the incidence generally increases with age also in the developed world.23–27 Hepatocellular carcinoma risk for chronic liver diseases of different etiologies. The prognosis of HCC patients is generally poor. Most studies report a 5-year survival rate of <5% in symptomatic HCC patients. Furthermore, these tumors have been shown to be quite resistant to radio- or chemotherapy. Investigations of the natural history and clinical course of HCC revealed long-term survival of patients only with small asymptomatic HCC that could be treated surgically or by non-surgical interventions.28 Most patients (>80%) are inoperable at the time of diagnosis. The prognosis of patients with inoperable HCC is very poor, the patient's estrogen receptor status being the strongest prognostic factor for survival.29 Unfortunately, despite progress in early diagnosis and surgical as well non-surgical treatment strategies, the overall survival of HCC patients has not significantly improved during the last two decades.30 Preventive strategies (Fig. 2) therefore are of paramount importance and need to be actively explored in order to reduce the incidence of HCC, one of the most devastating human malignancies worldwide. Hepatocellular carcinoma (HCC) development and strategies aimed at HCC prevention. 1, prevention of liver disease, for example by hygienic measures, prevention of exposure or vaccination against HBV infection, abstinence from alcohol etc. 2, prevention of chronic hepatitis, for example by treatment of acute hepatitis C, abstinence from alcohol, treatment of hereditary liver diseases etc. 3, prevention of liver cirrhosis, for example by antiviral treatment of chronic hepatitis B or C, treatment of other chronic liver diseases. 4, prevention of HCC development in liver cirrhosis, for example by antiviral treatment, inhibition of fibrosis, liver transplantation etc. Hepatitis B virus is a small DNA virus that belongs to the family of hepadnaviruses which includes the woodchuck hepatitis virus (WHV), ground squirrel hepatitis virus (GSHV), Pekin duck hepatitis B virus (DHBV) and heron hepatitis B virus (HHBV). The viral genome consists of a partially double-stranded DNA molecule of about 3200 nucleotides.31 The genetic organization of the viral genome and the viral proteins are known in great detail. There are five HBV genotypes and numerous HBV mutants as well as HBV quasispecies which have been detected in patients with acute and chronic hepatitis B. Epidemiologic studies have convincingly shown that HCC development is closely associated with chronic HBV infection.32 The incidence of HCC in chronically HBV-infected individuals is approximately 100-fold higher than in the uninfected population and the lifetime HCC risk of men infected at birth is estimated to approach 40%. Importantly, a recent study from Taiwan demonstrated a decline in the incidence of HCC in children after implementation of a universal hepatitis B vaccination program.33 A common molecular mechanism for HBV-induced hepatocarcinogenesis has not been discovered thus far, and both viral and host factors have been implicated in the process. On the one hand, most cases of HCC occur after many years of chronic hepatitis, which could provide the mitogenic and mutagenic environment to precipitate random genetic and chromosomal damage and lead to the development of HCC. In this context, in a transgenic mouse model it was recently shown that chronic immune-mediated liver cell injury is sufficient to cause HCC.34 On the other hand, several lines of evidence support a more direct oncogenic contribution of HBV to HCC development. Although HBV and retroviruses share a replication strategy that includes the reverse transcription of a RNA intermediate, viral integration into the host genome is not part of the HBV life cycle but rather occurs as an epiphenomenon of HBV replication. Integrated HBV sequences have been found by Southern blot analysis in the majority of HCC that develop in patients with chronic HBV infection (reviewed in 35,36). Detailed investigation of a number of different HBV integration sites has revealed that integration was random within human chromosomes. Therefore, HBV may act as a non-selective insertional mutagenic agent. In addition, secondary chromosomal rearrangements associated with HBV DNA integration, such as duplications, translocations, and deletions suggest that a major oncogenic effect of HBV integration may be an increased genomic instability. Deletions as well as translocations may result in the loss of cellular genes with important regulatory functions, thereby increasing the likelihood of cellular transformation. Only very few examples of HBV integrations within or near known functional cellular genes have been documented. In this regard, characterization of a single HBV integration site in an early HCC revealed that HBV inserted into an exon of the retinoic acid receptor (RAR) alpha gene, thereby resulting in overexpression of an aminoterminally truncated RAR alpha with altered functions (reviewed in 37). Further, it has recently been shown that phosphorylation of RAR alpha inhibits its degradation and enhances cell proliferation.38 Investigation of another HBV DNA integration site led to the identification of the human cyclin A gene.39 This integration had occurred within the second intron of the gene, resulting in the production of a spliced HBV-cyclin A fusion transcript. In the chimeric protein, the aminoterminal domain of cyclin A, containing the signals for regulated cyclin degradation, was replaced by viral pre-S2/S sequences, with transcription being initiated from the pre-S2/S promoter, while the carboxyterminal two-thirds of cyclin A, including the evolutionary well-conserved cyclin box, were intact. Constitutive and strong expression of this stabilized cyclin A protein may therefore have led to increased cell proliferation. These and a few additional similarly well characterized cases are notable exceptions, however, because HBV has not been found to commonly integrate in specific domains of known cellular genes. The HBV X gene product, termed HBx, can function as a transcriptional transactivator of various cellular genes associated with growth control and this phenomenon has led to the hypothesis that it may be involved in the development of HBV-associated HCC (reviewed in 40). Alternatively, it was postulated that HBx may promote hepatocarcinogenesis through activation of the Ras-Raf-MAP kinase pathway.41 In addition, malignant transformation of certain rodent cells,42 induction of cell cycle progression in quiescent mouse fibroblasts43 and Chang cells,44 and interference with cellular DNA repair45 as well as apoptosis46,47 have, among numerous other interactions with host cell functions, been described in different experimental systems. Recently it has been demonstrated that HBx triggers the release of calcium from mitochondria and/or the endoplasmic reticulum, that in turn triggers the calcium-dependent signaling pathway that affects many cellular processes, including transcription, translation, cell cycle control and apoptosis.48,49 A role of HBx in HBV-associated hepatocarcinogenesis is further supported by the observation that transgenic mice carrying the X gene under control of its own regulatory elements develop HCC.43,50 However, other investigators have not found tumors in HBx-transgenic mice.51 This discrepancy may be explained by differences in the level and duration of X gene expression and the genetic background of the mouse strains used in these studies. Recent studies suggested that HBx may, similar to gene products of other DNA tumor viruses, interact with p53 and may thereby interfere with the known functions of p53.52–54 However, it is presently unclear if such an interaction may have significance at HBx levels expressed in hepatocytes during natural HBV infection. In this context, Puisieux et al. found that HBV replication in Hep G2.2.15 cells did not interfere with p53 functions.55 Also, none of the various groups of investigators searching for HBx interactions with cellular proteins by the yeast two-hybrid system did, to our knowledge, find an interaction of HBx with p53. Thus, further studies are needed to clarify this intriguing issue. Another HBV gene product, which has been re-ported to possess transactivating properties, is a truncated pre-S2/S gene product referred to as truncated middle hepatitis B surface antigen (MHBst; reviewed in 40). A high rate of HCC has been found in woodchucks infected with WHV (reviewed in 56). Of the 63 experimentally infected chronic WHV carriers followed under controlled conditions at the woodchuck colony at Cornell University, all developed HCC by 3 years after experimental infection, compared to none of the uninfected animals.57 It is of considerable interest that HCC also occurred in 17 of 63 woodchucks that had serologically recovered from experimental WHV infection (negative for WHsAg, positive for anti-WHc and anti-WHs antibodies). The WHV DNA was detected in a substantial number of these tumors by Southern blot analysis.58 An increased incidence of HCC in HBsAg-negative individuals with serological evidence of past HBV infection (positive for anti-HBc and anti-HBs antibodies) has also been described. With the use of highly sensitive immunoassays and PCR, HBV has been shown to persist at low levels in a number of these subjects (reviewed in 59). Investigation of hepadnaviral integration sites to identify cellular oncogenes involved in HCC development was particularly rewarding in the case of HCC associated with chronic WHV infection (reviewed in 36). Activation of myc family oncogenes, presumably resulting from cis- and trans-acting effects of integrated WHV regulatory elements, was found in the majority of these tumors. Recently, it was also found that transgenic mice carrying a mutated c-myc gene and adjacent WHV DNA cloned in original configuration from a woodchuck HCC integration site developed liver tumors, thus underscoring the high oncogenic potential of insertionally activated myc family genes in this animal model.60 Finally, antisense downregulation of N-myc1 in woodchuck hepatoma cells has recently been shown to reverse the malignant phenotype.61 Although aflatoxin B1 (AFB1) does not induce HCC in uninfected woodchucks, in chronically WHV-infected animals HCC appears earlier and at a higher incidence, indicating a synergistic carcinogenic effect.62 Hepatitis C virus is the major agent causing perenterally transmitted post-transfusion or sporadic non-A, non-B hepatitis (NANB-H).63,64 Hepatitis C virus belongs to the Flaviviridae family and has a single-stranded RNA genome of positive polarity and known genetic organization. Infectious HCV cDNA clones have recently been constructed.65,66 Similar to HIV infection, in chronic HCV infection approximately 1011−1012 virions are produced daily.67,68 This high level of replication together with the lack of a proof-reading function of the viral RNA polymerase result in the rapid emergence of viral mutants and quasispecies. The HCV sequence analyses revealed substantial heterogeneity of HCV isolates.69 Depending on the degree of sequence homology, one distinguishes between genotypes (<72%), subtypes (73–84%) and isolates (85–99%). To date, at least six different HCV genotypes and several subtypes have been identified.70 Different genotypes can occur in a given geographic region albeit with different prevalences; they can even coexist in a given patient. In most chronically infected individuals HCV exists as quasispecies. Hepatitis C virus naturally infects only humans and experimentally chimpanzees. Apart from hepatocytes, other cells and tissues, in particular cells of the hematopoietic system, can probably also be infected by HCV.71 The clinical, immunological and virological factors affecting the natural course of HCV infection are not fully elucidated. Major histocompatibility complex (MHC) class I-dependent HCV-specific cytotoxic CD8-positive T lymphocytes,72 as well as MHC class II-dependent HCV-specific CD4-positive T lymphocytes, are clearly very important.73 Epidemiologic studies revealed the presence of anti-HCV antibodies as a marker of chronic hepatitis C in 15–80% of patients with HCC, depending upon the patient population studied (reviewed in 74,75). For example, HCV is a major cause of HCC in Japan, Italy, and Spain whereas it may play a less important role in South Africa and Taiwan. Similar to HBV, HCC associated with HCV infection evolves after many years of chronic infection and is generally preceded by the development of liver cirrhosis.76 Hepatitis C virus may be associated with HCC via chronic liver injury, as described in the previous section for HBV. However, recent clinical and experimental evidence raises the possibility that HCV might operate also through other pathways in promoting malignant transformation of hepatocytes. Hepatocellular carcinomas have been found in a series of chronically HCV-infected patients without liver cirrhosis.77 Moreover, a transforming potential of the aminoterminal portion of the NS3 protein78 and of the core protein79 have been described. In this context, the core protein has been reported to influence various cellular functions, including, among others, enhancement80 or inhibition79 of apoptosis and repression of p53,81 as well as p21WAF1 promoter activity.81 Most of these studies, however, were performed in experimental overexpression systems, and their relevance to natural HCV infection will need to be further addressed. Finally, HCC has recently been reported to develop in certain HCV core-transgenic mice.82 Central to the concept of molecular carcinogenesis are mutations of oncogenes and tumor suppressor genes as well as genetic instability of cellular DNA, including mismatch repair deficiency and impaired chromosomal segregation.83–87 In hepatocarcinogenesis, these genetic events occur in the setting of liver cell injury and necrosis associated with an increased rate of hepatocyte regeneration and mitosis. Any exogenous agent, viral or other, that contributes to chronic low-grade liver cell damage and mitosis potentially increases the risk of HCC development, rendering liver cell DNA susceptible to additional genetic alterations. Overall, there is a variety of molecular mechanisms by which environmental and viral carcinogens may play a role in HCC development.88–90 Activated cellular oncogenes, particularly those of the ras family, have been found in a number of experimental hepatocarcinogenesis models. In human hepatocarcinogenesis, however, no consistent pattern of protooncogene activation has emerged so far for HCC. It is also of interest that no structural or functional changes of a large panel of oncogenes have been found in a transgenic mouse model that is believed to resemble the process of human hepatocarcinogenesis. Restriction fragment length polymorphism studies of paired HCC and non-tumorous liver samples have revealed relatively frequent (>20% in ≥10 informative cases) chromosomal allelic losses (loss of heterozygosity, LOH) in HCC on chromosomes 4, 5q, 8p, 10q, 11p, 13q, 16, 16p and 16q, 17p and 22q, suggesting that these sites may harbor tumor suppressor genes involved in the pathogenesis of HCC. In general, these genetic alterations appear to occur at later stages of HCC development. Interestingly, a G to T mutation at the third base position of codon 249 of the p53 gene, leading to a substitution of to was found in a number of HCC in patients from southern Africa and the in It was suggested that this mutation was associated with high in and may have to the high incidence of HCC in these This was supported by in studies indicating that the third base of codon 249 of p53 was to with In to oncogenes and tumor suppressor DNA mismatch repair genes have recently been as a new class of genes involved in the pathogenesis of and sporadic human tumors, most hereditary DNA mismatch repair can lead to the of mutations and instability in the cellular genome and thus the of malignant transformation. The role of DNA mismatch repair in HCC development is Recent however, suggest that HBx may interfere with of the DNA repair The of or cell and may to cellular and as a control mechanism against cellular proliferation. Recently, a between certain of and the expression of a the of was expression of may be a common pathway leading to In this regard, in a recent study was found in of HCC in most other of the expression of growth factors and of of their signaling pathways may play an important role in hepatic overexpression of certain growth factors was found in HCC, including growth factor transforming growth and receptor hepatocyte growth factor has been shown to the growth of a number of hepatoma cell lines and no developed in transgenic mice in the liver under control of the Moreover, in a recent study in mice it was found that of The growth factors in HCC, however, is and additional factors are to as potentially important involved in hepatocarcinogenesis. or cDNA expression and other further of the genetic events underlying HCC pathogenesis and identification of as well as Hepatocellular carcinoma is one of the most common malignant tumors worldwide. The major risk factors for HCC development are well and of the involved in hepatocarcinogenesis have been in recent However, no of and in sequence these factors interact at the molecular level has emerged as transformation of hepatocytes may occur as a of various such as chronic viral hepatitis, alcohol, and in the of increased cellular by chronic liver injury, regeneration and cirrhosis. Activation of cellular oncogenes, of tumor suppressor overexpression of certain growth and activation and DNA mismatch repair may to the development of HCC. Finally, have been shown to induce specific mutations of the p53 tumor suppressor gene, thus to the contribution of environmental factors to tumor development at the molecular transformation occurs in the setting of chronic liver injury, cirrhosis and loss of growth control that to the development of HCC and is commonly preceded by genetic mutations and There are many factors that various in the process and may act viral hepatitis, alcohol, and certain may act through a pathway of chronic liver evidence that HBV may in play a more direct role in the molecular pathogenesis of HCC. hepatocyte growth at the molecular level may lead not only to a of the cellular events involved in hepatocyte but in all likelihood also to and Apart from HCC the and implementation of as well as the and development of strategies aimed at HCC prevention are most prevention has been shown to reduce HCC development in patient groups at For example, hepatitis B vaccination of children in Taiwan has in a decline of the HCC Further, antiviral of patients with chronic hepatitis B or C to HCC prevention. to reduce with and alcohol use also reduce the incidence of chronic liver disease, cirrhosis and thereby HCC. Apart from HCC aimed at secondary prevention after HCC treatment are also a very of and clinical In the therefore have a major on the incidence of HCC, one of the most common and devastating malignancies in the